

|                          |   |
|--------------------------|---|
| <b>Product Name</b>      | : Deslanoside   |
| <b>Synonyms</b>          | : Deacetyllanatoside C;Desacetyllanatoside C  |
| <b>Cat No.</b>           | : M21488  |
| <b>CAS Number</b>        | : 17598-65-1  |
| <b>Molecular Formula</b> | : C47H74O19   |
| <b>Formula Weight</b>    | : 943.1   |
| <b>Chemical Name</b>     | 4-(3S5R8R9S10S12R13S14S17R)-1214-dihydroxy-3-((2R4S5S6R)-4-hydroxy-5-((2S4S5S6R)-4-hydroxy-6-methyl-5-((2S3R4S5S6R)-345-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)tetrahydro-2H-pyran-2-yl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6-methyltetrahydro-2H-pyran-2-yl)oxy)-1013-dimethylhexadecahydro-1H-cyclopenta[a]phenanthren-17-yl)furan-2(5H)-one |
| <b>Description</b>       | : Deslanoside is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms. Deslanoside inhibits the Na-K-ATPase membrane pump resulting in an increase in intracellular sodium and calcium concentrations.  |
| <b>Pathway</b>           | : Endocrinology/Hormones  |
| <b>Target</b>            | : ATPase  |
| <b>Receptor</b>          | : Na+/K+-ATPase   |
| <b>Solubility</b>        | : _____   |
| <b>SMILES</b>            | : C[C@H]1[C@H](C[C@H](C[C@H](O1)OC[C@H]2CC[C@]3([C@@H](C2)CC[C@H]4[C@@H]3C[C@H]([C@]5([C@@H]4(CC[C@H]5C6=CC(=O)OC6)OC)OC)OC)[C@H]7C[C@H]([C@@H]([C@H]([C@H](O7)C)OC[C@H]8C[C@H]([C@@H]([C@H](O8)C)OC[C@H]9C[C@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O)O)  |
| <b>Storage</b>           | : (-20°C)   |
| <b>Stability</b>         | : ≥ 2 years   |
| <b>Reference</b>         | :   |

1.Hauptman PJ et al. Digitalis. Circulation. 1999 Mar 9;99(9):1265-70.